Kardigan, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing precision medicines for cardiovascular diseases with high unmet medical needs. The company's business model centers on in-licensing and advancing late-stage therapeutic candidates that target the underlying pathophysiology of heart conditions, moving beyond traditional symptom management. Kardigan's pipeline includes three primary clinical-stage programs: danicamtiv, an oral cardiac myosin activator for genetic dilated cardiomyopathy (DCM); ataciguat, a soluble guanylate cyclase activator for moderate calcific aortic valve stenosis (CAVS); and tonlamarsen, an antisense oligonucleotide for acute severe hypertension (ASH). A key differentiator for Kardigan is its proprietary "Cardiac Intelligence" platform, which incorporates Prolaio's cardiovascular data collection and analytics technology. This platform utilizes artificial intelligence, FDA-cleared algorithms, and high-density patient data from wearable devices to enhance clinical study design, improve patient responder matching, and track efficacy. By integrating deep cardiovascular biology with advanced analytics, Kardigan aims to accelerate drug development and increase the probability of clinical success. The company operates primarily in the United States, with offices in Princeton, New Jersey, and South San Francisco, California. As a pre-revenue clinical-stage biotech, Kardigan relies on venture capital and public market funding to advance its pipeline toward commercialization.
Gross margin measures the amount of revenue that remains after subtracting costs directly associated with production.
The EBITDA margin is a measure of a company's operating profit desconsidering D&A costs as a percentage of its revenue.
The EBIT margin is a measure of a company's operating profit considering D&A costs as a percentage of its revenue.
The net profit margin, or simply net margin, measures how much net income or profit is generated as a percentage of revenue. It is the ratio of net profits to revenues for a company or business segment.
Many companies have a high D&A in relation to the company's operating profit (EBITDA) and although this indicator does not have an effective cash effect, it ends up influencing the accounting net income, so analyzing this relationship can help to understand when D&A has a relevant impact to the company's results.
Shows the amount spent on investments in research and development in relation to the Net Revenue for the period. The company can use these investments to try to increase its revenue in the future.
Shows the amount spent on investments in Capex in relation to Net Revenue for the period. The company can use these investments to try to increase its revenue in the future.
Indicates a comparison between investments in fixed/intangible assets and the depreciation and amortization of some company assets. It serves to let managers know that the company's assets are devaluing periodically, and whether CAPEX has followed the same pace or not.
It shows the percentage of operating cash flow that the company uses in Capex (investments in fixed and intangible assets). When your result is greater than 100%, it demonstrates that there are expenses greater than what the company produces in its operations.
It demonstrates the percentage cost of Stock-Based Compensation compared to the company's operating cash flow. In some companies, the OCF is positive because of the SBC, which can lead to an incorrect cash flow analysis.
If the company has a lot of D&A, it helps to see if most of it tends to come from fixed assets. The account can include machinery, equipment, vehicles, buildings, land, office equipment, and furnishings, among other things.
If the company has a lot of D&A, it helps to see if most of it tends to come from Goodwill, that is an intangible asset that accounts for the excess purchase price of another company.
Return on equity (ROE) is the measure of a company's net income divided by its shareholders' equity and is a gauge of a corporation's profitability and how efficiently it generates those profits.
Return on invested capital (ROIC) is a calculation used to assess a company's efficiency in allocating capital to profitable investments. The formula for calculating ROIC involves dividing Net Income by the average of invested capital.
...and much more!